Genmab · 2 hours ago
Business Operations and Analytics Intern - US Market Commercial
Princeton
Internship
Hybrid
Intern
Start in 2026 SummerGenmab is an international biotechnology company dedicated to improving the lives of patients through innovative antibody therapeutics. The Business Operations and Analytics Intern will support the U.S. Commercial organization by working on projects that enhance data integrity, financial reporting, and analytics, while gaining insights into business operations.
BiotechnologyHealth CareManufacturingMedical
No H1B
Responsibilities
Gather and document business requirements in partnership with U.S. Commercial stakeholders to support analytics, reporting, and operational initiatives
Collect, process, and validate data from CRM, financial, and commercial systems, ensuring high standards of data integrity, quality, and consistency
Perform data quality reviews, reconciliation, and validation to ensure analytical accuracy and reliability
Develop and support dashboards, reports, and ad hoc analyses using tools such as Tableau and Salesforce Life Sciences Cloud
Apply sound analytical methods and maintain clear documentation of assumptions, methodologies, and data sources to ensure analytical rigor
Support financial modeling and commercial analyses that inform market targeting, opportunity assessment, and investment decision-making
Qualification
Required
Currently pursuing a Bachelor's degree in Business, Finance, Economics, Analytics, or a related field. May 2026 graduates will be considered
Strong analytical skills with the ability to work with data, identify issues, and draw meaningful insights
Demonstrated interest in learning the capabilities and operating model of a biotechnology commercial organization
Proficiency in Excel
Curious, detail-oriented, and eager to learn in a fast-paced, data-driven environment
Preferred
Experience in analytics, financial modeling, data analysis, or business intelligence
Company
Genmab
Genmab is a biotechnology company focused on developing fully human antibody therapeutics for the potential treatment of cancer.
Founded in 1999
1001-5000 employees
Funding
Current Stage
Public CompanyTotal Funding
$11.7BKey Investors
Morgan Stanley Senior FundingGlaxoSmithKlineIndex Ventures
2025-11-18Post Ipo Debt· $6B
2025-09-29Post Ipo Debt· $5.5B
2010-07-01Post Ipo Equity· $134M
Leadership Team
Anthony Pagano
Chief Financial Officer
Anthony Mancini
EVP & Chief Operating Officer
Recent News
2026-01-11
Pharma Letter
2026-01-09
2026-01-09
Company data provided by crunchbase